Cart
sales@molnova.com
AEF0117
CAS No. 1610878-71-1
AEF0117( —— )
Catalog No. M37258 CAS No. 1610878-71-1
AEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1-SSi), inhibits cannabinoid self-administration and behavioral disorders associated with THC, and can be used to study cannabis withdrawal.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 46 | Get Quote |
|
| 5MG | 61 | Get Quote |
|
| 10MG | 93 | Get Quote |
|
| 25MG | 182 | Get Quote |
|
| 50MG | 302 | Get Quote |
|
| 100MG | 484 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | 1035 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAEF0117
-
NoteResearch use only, not for human use.
-
Brief DescriptionAEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1-SSi), inhibits cannabinoid self-administration and behavioral disorders associated with THC, and can be used to study cannabis withdrawal.
-
DescriptionAEF0117 a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 plays an important role in Cannabis use disorder (CUD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCannabinoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610878-71-1
-
Formula Weight436.63
-
Molecular FormulaC29H40O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)[C@@H](C(C)=O)CC4)[H])(CC=C1C[C@@H](OCC5=CC=C(OC)C=C5)CC2)[H])[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Margaret Haney, et al. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nat Med. 2023 Jun;29(6):1487-1499.?
molnova catalog
related products
-
A 834735
A potent, nonselective, brain penetrant, full agonist at both the central CB1 and peripheral CB2 receptors with Ki of 4.6 and 0.31 nM, respectively.
-
CB1 antagonist 2
CB1 antagonist 2 is caimabinoid 1 (CB1) antagonist extracted from patent WO2016184310A1, compound 3. Which inhibits CB1 in vivo with an IC50 of 25.5 nM.
-
Otenabant
A potent, and selective CB1 receptor antagonist with Ki of 0.7 nM/0.12 nM in binding and functional assays respectively; has low affinity (Ki=7600 nM) for human CB2 receptors; reverses cannabinoid agonist mediated responses, reduces food intake, and increases energy expenditure and fat oxidation in rodents.ObesityPhase 3 Discontinued
